Bodytechmed Signs Contract with German Sphingotec for Acute Kidney Injury Biomarker Introduction

Bodytech Med exterior. [Photo by Bodytech Med]

[Asia Economy Reporter Lee Gwanju] Boditech Med announced on the 15th that it has signed a non-exclusive license agreement with the German biomarker development specialist company 'Sphingotec' for the biomarker 'Penkid (Proenkephalin A 119-159)' that measures acute kidney injury.

Through this agreement, Boditech Med has acquired the rights to develop and commercialize the Penkid diagnostic kit applied to the point-of-care diagnostic platforms 'ichroma' and 'AFIAS'. Sphingotec holds the worldwide exclusive rights to Penkid, a biomarker that measures acute kidney injury in critically ill patients through blood.

Penkid is a biomarker that complements the drawbacks of existing kidney function measurement methods, which are complex and time-consuming, allowing for simple and rapid confirmation of kidney injury. It is especially useful for medical staff treating critically ill patients in emergency wards by providing fast and accurate information related to the patient's kidney function, helping to assess critical patient conditions.

Boditech Med plans to strengthen collaboration with the Sphingotec group on severe diseases, starting with Penkid. Sphingotec is a provider of innovative biomarkers necessary for predicting and diagnosing acute severe diseases such as acute heart failure and acute kidney injury, and also holds exclusive rights to sepsis-related biomarkers.

J?rg Menten, CEO of Sphingotec, said, "Boditech Med is a global leader in the point-of-care diagnostics field, supplying point-of-care diagnostic platforms worldwide," adding, "With this agreement, more medical staff will be able to quickly and accurately check the kidney status of critically ill patients through Penkid."

Choi Eui-yeol, CEO of Boditech Med, stated, "This agreement expands the product range used for critically ill patients," and added, "We will successfully apply Penkid to our diagnostic solutions to focus on early detection of acute kidney injury and strengthen collaboration with the Sphingotec group on severe diseases in the future."